NCT05949879Completed
Dose Response Effects of Pecan Consumption
Source: ClinicalTrials.gov · Last updated 4 May 2026
Brief summary (registry, in English)
The bioactive compounds contained in tree nuts have been shown to beneficially affect cardiometabolic health outcomes. Pecans contain more total phenols, sterols, and flavonoids than any other tree nut. They also are a rich source of polyunsaturated fatty acids (PUFAs), fiber, vitamin A, vitamin E, folic acid, calcium, magnesium, phosphorus, potassium, and zinc. These bioactive components in pecans are likely the reason for the previously documented improvements in cardiometabolic health. The specific aims of this study are to: * Examine the effect of pecan consumption at doses of 6%, 13%, and 20% of total energy needs on fasting and postprandial blood lipids. * Examine the effect of pecan consumption at doses of 6%, 13%, and 20% of total energy needs on plasma markers associated with overall health. * Examine the effect of pecan consumption at doses of 6%, 13%, and 20% of total energy needs on subjective and physiologic postprandial measures of hunger and satiety. Participants will be asked to: * Consume pecans daily for 28 days or maintain their current habitual diet. * Attend three short weekly visits for fasting blood craws, body measurements, and collect their next week's supply of study materials. * Attend two longer (5 h) testing visits which include consuming a standard breakfast meal and having their blood drawn periodically before and after breakfast. Researchers will compare pecan LOW, pecan MID, pecan HIGH, and the Control group to examine the physiologic effects of incorporating various dosages of pecans into one's diet.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 108 (actual)
- First submitted
- 28 Jun 2023
- Start date
- 1 Aug 2023
- Primary completion date
- 14 Apr 2025
- Lead sponsor
- University of Georgia
- Diseases
- Obesity
- NCT number
- NCT05949879
What you commit to
- Study type: Interventional
- Participants enrolled: 108
- From 1 Aug 2023 to the primary completion date, 14 Apr 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- History of previous or current renal or bowel disease
- Previous heart attack (MI) or stroke, previous or current diagnosis of cancer
- Steroid/hormone therapies or current antibiotic cycles
Other illness
- Individuals with food allergies/sensitivities to foods provided in the study, including tree nuts, gluten, and or lactose/dairy
- History of medical or surgical events that could affect digestion or swallowing
- Gastrointestinal surgery, atherosclerosis, or bleeding disorders
- Chronic or metabolic diseases
- Medication use affecting digestion and absorption, medications affecting metabolism (e.g., thyroid meds), lipid-lowering medications, medications for diabetes, blood thinning medications
Lab values
- Probable familial hypercholesterolemia, defined by: total cholesterol greater than 290 mg/dL or LDL levels greater than 190 mg/dL plus a family history of myocardial infarction (MI) before 50 years of age in a 2nd-degree relative or below age 60 in a 1st-degree relative
- Fasting glucose \>126 mg/dL
Age
- Women on hormone replacement therapy for \<2 years
Other
- Alcohol intake \>3 drinks/d for males or \>2 drinks/d for females
- Individuals who regularly consume nuts and/or nut butter (defined as consumption of \>2 servings (\~56g) of tree nuts, nuts, or nut butter (e.g., peanut butter, almond butter) per week
- Individuals adhering to special diets, including, but not limited to, the ketogenic diet, intermittent fasting, vegetarian diet, or carbohydrate-restricted diets
- Plans to begin a weight loss/exercise regime during the trial
- Weight gain or loss of more than 5% of their body weight in the past 3 months
- Females who are currently pregnant or lactating
- Individuals participating in \>3 hours/week of exercise
- Blood pressure \>180/120 mmHg
- Tobacco or nicotine use
Who the study is looking for
- 30 to 75-year-old men and women at increased risk of cardiovascular disease. Increased risk of cardiovascular disease will be defined by either elevated cholesterol profiles or overweight/obesity.
- Elevated cholesterol profiles will be defined as: "Borderline High" and/or "at risk" in two or more of the following variables (total cholesterol: 180-239 mg/dL, LDL cholesterol 110- 159 mg/dL, triglycerides 130-199 mg/dL) --or---"High" in total cholesterol (240 mg/dL and higher), LDL (160 mg/dL or higher), or triglycerides (between 200-350 mg/dl).
- Overweight/obesity will be defined by body mass index (overweight \> 28 kg/m2 or obesity 30 kg/m2 or greater).
Age in the registry: 30 years to 75 years · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University of Georgia Coordinator of this site? Confirm its status | Athens | United States | Unknown status |
Related publications
This page is information, not medical advice. Discuss any trial with your doctor.